Department of Pharmacy, University G. d'Annunzio, Chieti-Pescara, via dei Vestini 31, Chieti Scalo, Italy.
Department of Pharmacy, University G. d'Annunzio, Chieti-Pescara, via dei Vestini 31, Chieti Scalo, Italy.
Neurochem Int. 2019 Jun;126:239-245. doi: 10.1016/j.neuint.2019.03.021. Epub 2019 Apr 1.
The worldwide increase in aging population is prevalently associated with the increase of neurodegenerative diseases. Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-modulated transcriptional factors which belong to the nuclear hormone receptor superfamily which regulates peroxisome proliferation. The PPAR-γ is the most extensively studied among the three isoforms and the neuroprotective effects of PPAR-γ agonists have been recently demonstrated in a variety of preclinical models of neurological disorders. The aim of the study is to biologically evaluate the neuroprotective effects of new PPAR-γ selective agonists in an in vitro model.
CTX-TNA2 rat astrocytes were treated with G3335, a PPAR-γ antagonist, to simulate the conditions of a neurological disorder. Newly synthetized PPAR-γ selective agonists were added to the cell culture. Cytotoxicity was assessed by MTT assay, catalase activity was investigated by a colorimetric assay, Reactive Oxygen Species (ROS) production and apoptosis occurrence were measured by flow cytometry. Western blotting were performed to measure the levels of protein involved in the apoptotic pathway.
Four PPAR-γ agonists were selected. Among them, the GL516, a fibrate derivative, showed low cytotoxicity and proved effective in restoring the catalase activity, reducing ROS production and decreasing the apoptosis occurrence triggered by the G3335 administration. The effects of this molecule appear to be comparable to the reference compound rosiglitazone, a potent and selective PPAR-γ agonist, mainly at prolonged exposure times (96 h).
Based on recent evidence, hypofunctionality of the PPAR-γ in glial cells could be present in neurodegenerative diseases and could participate in pathological mechanisms through peroxisomal damage. The fibrate derivative PPAR-γ agonist GL516 emerged as the most promising molecule of the series and could have a role in preventing the pathophysiology of neurodegenerative disorders.
全球人口老龄化的增加与神经退行性疾病的增加密切相关。过氧化物酶体增殖物激活受体 (PPAR) 是配体调节的转录因子,属于核激素受体超家族,可调节过氧化物酶体增殖。在三种同工型中,PPAR-γ 研究最为广泛,最近在多种神经疾病的临床前模型中证明了 PPAR-γ 激动剂的神经保护作用。本研究的目的是在体外模型中对新型 PPAR-γ 选择性激动剂的神经保护作用进行生物学评估。
用 PPAR-γ 拮抗剂 G3335 处理 CTX-TNA2 大鼠星形胶质细胞,模拟神经疾病的条件。将新合成的 PPAR-γ 选择性激动剂添加到细胞培养物中。通过 MTT 测定法评估细胞毒性,通过比色法测定过氧化氢酶活性,通过流式细胞术测量活性氧 (ROS) 产生和细胞凋亡发生。通过 Western blot 测定法测量参与凋亡途径的蛋白质水平。
选择了四种 PPAR-γ 激动剂。其中,纤维酸衍生物 GL516 表现出低细胞毒性,并被证明有效恢复过氧化氢酶活性,降低 ROS 产生,并减少 G3335 给药引发的细胞凋亡。这种分子的作用似乎与参考化合物罗格列酮相当,罗格列酮是一种有效的选择性 PPAR-γ 激动剂,主要在延长的暴露时间(96 小时)内有效。
基于最近的证据,神经退行性疾病中可能存在神经胶质细胞中 PPAR-γ 的功能障碍,并且可能通过过氧化物酶体损伤参与病理机制。纤维酸衍生物 PPAR-γ 激动剂 GL516 作为该系列中最有前途的分子出现,可能在预防神经退行性疾病的病理生理学方面发挥作用。